Your browser doesn't support javascript.
loading
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq, Gabrielle; Haegel, Hélène; Toso, Alberto; Zimmermann, Tina; Green, Luke; Steinhoff, Nathalie; Sam, Johannes; Pulko, Vesna; Schneider, Anneliese; Giusti, Anna Maria; Challier, John; Freimoser-Grundschober, Anne; Larivière, Laurent; Odermatt, Alex; Stern, Martin; Umana, Pablo; Bacac, Marina; Klein, Christian.
Afiliación
  • Leclercq G; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland gabrielle.leclercq@roche.com.
  • Haegel H; Department of Pharmaceutical Sciences, Division Molecular and Systems Toxicology, University of Basel, Basel, Switzerland.
  • Toso A; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Zimmermann T; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Green L; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Steinhoff N; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Sam J; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Pulko V; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Schneider A; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Giusti AM; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Challier J; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Freimoser-Grundschober A; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Larivière L; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Odermatt A; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Stern M; Department of Pharmaceutical Sciences, Division Molecular and Systems Toxicology, University of Basel, Basel, Switzerland.
  • Umana P; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Bacac M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Klein C; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
J Immunother Cancer ; 10(1)2022 01.
Article en En | MEDLINE | ID: mdl-35064010
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Citocinas / Anticuerpos Biespecíficos / Inhibidores de las Cinasas Janus / Inhibidores mTOR / Inmunoterapia Límite: Animals / Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Citocinas / Anticuerpos Biespecíficos / Inhibidores de las Cinasas Janus / Inhibidores mTOR / Inmunoterapia Límite: Animals / Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Reino Unido